Trial reportThe American journal of gastroenterology2011
Randomized comparison of three palliative regimens including brachytherapy, photodynamic therapy, and APC in patients with malignant dysphagia (CONSORT 1a) (Revised II).
Trial report in The American journal of gastroenterology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- Interventions for dysphagia in oesophageal cancer.The Cochrane database of systematic reviews · 2014Pooled it
- German guidelines for the diagnosis and treatment of squamous-cell carcinoma and adenocarcinoma of the esophagus-version 4.0.ESMO gastrointestinal oncology · 2025Review
- Endoscopic spray cryotherapy for dysphagia palliation in esophageal cancer: Systematic review and meta-analysis.Endoscopy international open · 2024Article
- Special immune-related adverse events and subsequent photodynamic therapy in tislelizumab treatment for esophageal cancer: a case report.Frontiers in immunology · 2024Article
- Endoscopic Management of Esophageal Cancer.Cancers · 2022Review
- Optimal Management of Dysphagia in Patients with Inoperable Esophageal Cancer: Current Perspectives.Cancer management and research · 2022Review
- Photodynamic therapy: A next alternative treatment strategy for hepatocellular carcinoma?World journal of gastrointestinal surgery · 2021Article
- Reducing dysphagia with palliative 2D high-dose-rate brachytherapy improves survival in esophageal cancer.Journal of contemporary brachytherapy · 2019Article
- Scoping review on interventions to improve adherence to reporting guidelines in health research.BMJ open · 2019Article
- Evaluation on Short-Term Therapeutic Effect of 2 Porphyrin Photosensitizer-Mediated Photodynamic Therapy for Esophageal Cancer.Technology in cancer research & treatment · 2019Article
- Treatment for unresectable or metastatic oesophageal cancer: current evidence and trends.Nature reviews. Gastroenterology & hepatology · 2018Review
- Argon plasma coagulation compared with stent placement in the palliative treatment of inoperable oesophageal cancer.United European gastroenterology journal · 2017Article
- High dose-rate endoluminal brachytherapy for primary and recurrent esophageal cancer : Experience from a large single-center cohort.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2016Article
- Palliation of Dysphagia in Carcinoma Esophagus.Clinical medicine insights. Gastroenterology · 2016Review
- Definitive, Preoperative, and Palliative Radiation Therapy of Esophageal Cancer.Viszeralmedizin · 2015Review
- Palliative Endoscopic Therapy of Esophageal Cancer.Viszeralmedizin · 2015Review
- Making research articles fit for purpose: structured reporting of key methods and findings.Trials · 2015Article
- [Curietherapy in the palliative treatment of esophageal cancer].The Pan African medical journal · 2015Article
- Intraluminal brachytherapy in oesophageal cancer: defining its role and introducing the technique.Journal of contemporary brachytherapy · 2014Review
- Role of photodynamic therapy in the palliation of obstructing esophageal cancer.The Korean journal of internal medicine · 2012Article
Corrections and comments
- Commented on by
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesBecause most esophageal cancers are diagnosed at an advanced stage, a majority of patients require palliative dysphagia treatment. Dysphagia severity and the need for repeated re-canalization procedures significantly affect patients' quality of life (QoL). The aim of this study was to establish whether combining argon plasma coagulation (APC) of the neoplastic esophageal tissue with another re-canalization method results in a longer dysphagia-free period compared with APC alone.
methodsWe conducted a randomized trial in 93 patients with malignant dysphagia. Patients were followed until death. We compared three regimens of esophageal re-canalization; APC combined with high dose rate (HDR) brachytherapy, APC combined with photodynamic therapy (PDT), and APC alone. The primary outcome measure was the dysphagia-free period following randomization. Secondary measures were survival, QoL, treatment-associated complications, and treatment tolerance. A per-protocol analysis was carried out.
resultsThe time to first dysphagia recurrence was significantly different between each combination treatment group and the control group (overall test: P=0.006; HDR vs. control, log-rank P=0.002, PDT vs. control, log-rank P=0.036), but not different between the combination groups (HDR vs. PDT, log-rank P=0.36). The median time to first dysphagia recurrence was 88, 59, and 35 days in the HDR, PDT, and control groups, respectively. There was no difference in overall survival between the study groups (P=0.27). No deaths, perforations, hemorrhages, or fistula formations were attributed to treatment. The only major complication was fever, occurring in three PDT patients. Minor complications were observed significantly more often in the combination treatment groups and included pain in both groups, transient dysphagia worsening, and skin sensitivity in the PDT group. The QoL 30 days after treatment in the HDR group was significantly better than in the other groups.
conclusionsIn patients with inoperable esophageal cancer, palliative combination treatment of dysphagia with APC and HDR or PDT was significantly more efficient than APC alone, and was safe and well tolerated. APC combined with HDR resulted in fewer complications and better QoL than APC with PDT or APC alone (CONSORT 1b).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.